Press release
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc
An investigation on behalf of investors of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE).
Investors who purchased shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and currently hold any of those NASDAQ: CERE shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Cerevel Therapeutics Holdings, Inc. breached their fiduciary duties owed to NASDAQ: CERE investors in connection with the proposed acquisition.
Cambridge, MA based Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. On December 06, 2023, AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) announced an agreement under which AbbVie will acquire Cerevel Therapeutics. Under the terms of the transaction AbbVie Inc. (NYSE: ABBV) will acquire all outstanding Cerevel Therapeutics (NASDAQ: CERE) common stock for $45.00 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ: CERE stockholders. More specifically, the investigation concerns whether the Cerevel Therapeutics Holdings, Inc. Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc here
News-ID: 3478027 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Cerevel
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerev …
DelveInsight's, "Parkinson's disease - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Parkinson's Disease pipeline includes over 130…
Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treat …
(Albany, USA) DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Schizophrenia, including historical and forecasted epidemiology, as well as Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The Schizophrenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Schizophrenia market size from 2020 to 2034,…
Panic Disorder Market on Track for Major Expansion by 2032, According to DelveIn …
DelveInsight's "Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Panic Disorder, offering comprehensive insights into the Panic Disorder revenue trends, prevalence, and treatment landscape. The…
Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeuti …
DelveInsight's, "Parkinson's Disease- Pipeline Insight, 2025" report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 130 prominent companies are actively involved in…
Panic Disorder Market Statistics Expected to Experience Major Growth by 2032, Ac …
The Key Panic Disorder Companies in the market include - Pfizer, Honeybrains Biotech LLC, Cerevel Therapeutics, Massachusetts General Hospital, Samsung Medical Center, Indiana University, UCB Pharma, and others.
DelveInsight's "Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Parkinson's disease Market to Witness Growth by 2032, Estimates DelveInsight | C …
(Albany, USA) DelveInsight's "Parkinson's disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Parkinson's disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson's disease…
